JP2003506362A - Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体 - Google Patents

Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体

Info

Publication number
JP2003506362A
JP2003506362A JP2001514309A JP2001514309A JP2003506362A JP 2003506362 A JP2003506362 A JP 2003506362A JP 2001514309 A JP2001514309 A JP 2001514309A JP 2001514309 A JP2001514309 A JP 2001514309A JP 2003506362 A JP2003506362 A JP 2003506362A
Authority
JP
Japan
Prior art keywords
triazole
amino
anilino
formula
carboxylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001514309A
Other languages
English (en)
Japanese (ja)
Inventor
デイビッド・グリン・スミス
ロバート・ウィリアム・ウォード
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Ltd
Original Assignee
SmithKline Beecham Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd
Publication of JP2003506362A publication Critical patent/JP2003506362A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/14—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
JP2001514309A 1999-08-02 2000-07-31 Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体 Pending JP2003506362A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9918180.2A GB9918180D0 (en) 1999-08-02 1999-08-02 Novel compositions
GB9918180.2 1999-08-02
PCT/EP2000/007423 WO2001009106A1 (fr) 1999-08-02 2000-07-31 Composes diamino-1,2,4-triazole-acide carboxylique et derives de ces derniers utiles en tant qu'inhibiteurs de gsk-3

Publications (1)

Publication Number Publication Date
JP2003506362A true JP2003506362A (ja) 2003-02-18

Family

ID=10858425

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001514309A Pending JP2003506362A (ja) 1999-08-02 2000-07-31 Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体

Country Status (5)

Country Link
EP (1) EP1200415A1 (fr)
JP (1) JP2003506362A (fr)
AU (1) AU6989800A (fr)
GB (1) GB9918180D0 (fr)
WO (1) WO2001009106A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507080A (ja) * 2005-09-07 2009-02-19 リゲル ファーマシューティカルズ，インコーポレーテッド Ａｘｌ阻害剤として有用なトリアゾール誘導体
JP2015525743A (ja) * 2012-07-06 2015-09-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス剤としてのトリアゾール化合物

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1286964B1 (fr) 2000-05-11 2007-07-04 Consejo Superior de Investigaciones Cientificas Inhibiteurs heterocycliques de la glycogene synthase kinase gsk-3
ES2166328B1 (es) * 2000-05-11 2003-09-16 Consejo Superior Investigacion Inhibidores heterociclicos del enzima gsk 3 utiles en el tratamiento de procesos neurodegenerativos e hiperproliferativos
PT1355889E (pt) * 2000-12-22 2006-09-29 Ortho Mcneil Pharm Inc Derivados diamina triazole substituidos como inibidores de cinase
EP1712550A3 (fr) * 2000-12-22 2009-07-15 Ortho-McNeil Pharmaceutical, Inc. Dérivés de triazole diamine substitués comme inhibiteurs de kinases
GB0103031D0 (en) * 2001-02-07 2001-03-21 Smithkline Beecham Plc Novel treatment
EP1417188A1 (fr) * 2001-08-03 2004-05-12 Novo Nordisk A/S Nouveaux derives de la 2,4-diaminothiazole
TW201041580A (en) * 2001-09-27 2010-12-01 Alcon Inc Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
CA2581126A1 (fr) 2004-09-24 2006-04-06 Rfe Pharma Llc Systemes bases sur cai et methodes de traitement localise de maladies oculaires et autres
US20160106717A1 (en) 2004-09-24 2016-04-21 Gen Pharma Holdings LLC Cai-based systems and methods for the localized treatment of uveitis
BRPI0516569A (pt) 2004-10-08 2008-09-16 Janssen Pharmaceutica Nv derivados de 1,2,4-triazolilaminoaril(heteroaril)sulfonamida
EP2258358A3 (fr) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenèse avec un inhibiteur de l'acetylcholinestérase
EP2275095A3 (fr) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenese par modulation des recepteurs muscariniques
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
CA2625210A1 (fr) 2005-10-31 2007-05-10 Braincells, Inc. Modulation de la neurogenese dont la mediation est assuree par recepteur gaba
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
EP2114954B1 (fr) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Triazoles à substitution aryle bicycliques et hétéroaryle bicycliques utiles en tant qu'inhibiteurs axl
ME01832B (me) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Policiklični heteroaril supstituisani triazoli koji su korisni kao axl inhibitori
EP2114955B1 (fr) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle bicyclique ponté et hétéroaryle bicyclique ponté utilisés comme inhibiteurs d'axl
JP5567837B2 (ja) * 2006-12-29 2014-08-06 ライジェル ファーマシューティカルズ， インコーポレイテッド Ａｘｌインヒビターとして有用なＮ３−ヘテロアリール置換トリアゾールおよびＮ５−ヘテロアリール置換トリアゾール
CN110551105B (zh) 2006-12-29 2022-10-18 里格尔制药公司 用作axl抑制剂的取代三唑
WO2009054864A1 (fr) 2007-10-26 2009-04-30 Rigel Pharmaceuticals, Inc. Triazoles substitués par aryle polycyclique et triazoles substitués par hétéroaryle polycyclique utiles comme inhibiteurs d'axl
WO2010005879A1 (fr) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Triazoles substitués par hétéroaryle bicycliques pontés utiles comme inhibiteurs de axl
WO2010005876A2 (fr) 2008-07-09 2010-01-14 Rigel Pharmaceuticals, Inc. Triazoles à substitution hétéroaryle polycycliques utiles en tant qu’inhibiteurs d’axl
ES2528032T3 (es) 2009-01-16 2015-02-03 Rigel Pharmaceuticals, Inc. Inhibidores de Axl para su uso en terapia de combinación para prevenir, tratar o manejar cáncer metastásico
WO2010099217A1 (fr) 2009-02-25 2010-09-02 Braincells, Inc. Modulation de neurogenèse à l'aide de combinaisons de d-cyclosérine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2352944A (en) * 1942-07-04 1944-07-04 Gen Electric Triazole derivatives
FI850994L (fi) * 1984-03-16 1985-09-17 Ciba Geigy Ag Foerfarande foer framstaellning av nya 1,2,4-triazacykloalkadienderivat.
EP1112070B1 (fr) * 1998-08-20 2004-05-12 Smithkline Beecham Corporation Nouveaux composes de triazole substitues

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009507080A (ja) * 2005-09-07 2009-02-19 リゲル ファーマシューティカルズ，インコーポレーテッド Ａｘｌ阻害剤として有用なトリアゾール誘導体
JP2015525743A (ja) * 2012-07-06 2015-09-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 抗ウイルス剤としてのトリアゾール化合物

Also Published As

Publication number Publication date
EP1200415A1 (fr) 2002-05-02
AU6989800A (en) 2001-02-19
GB9918180D0 (en) 1999-10-06
WO2001009106A1 (fr) 2001-02-08

Similar Documents

Publication Publication Date Title
JP2003506362A (ja) Ｇｓｋ−３阻害剤としてのジアミノ−１，２，４−トリアゾール−カルボン酸誘導体
US7105532B2 (en) Pyrazolo[3,4-c]pyridines as gsk-3 inhibitors
JP4714686B2 (ja) 新規のγ−セクレターゼ阻害剤
EP1119548B1 (fr) 3-(3-chloro-4-hydroxyphenylamino)-4-(2-nitrophenyl)-1h-pyrrole-2,5-dione utile comme inhibiteur de glycogen synthase kinase-3 (gsk-3)
US20030149034A1 (en) Indazoles substituted with1,1-dioxoisothiazolidine useful as inhibitors of cell proliferation
JP2003507476A (ja) Ｎｏｓ阻害剤としてのｎ−複素環式誘導体
CA2988147A1 (fr) Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires
KR20010080599A (ko) 아미노피라졸 유도체
JP2006515588A (ja) ２−置換４−ヘテロアリールピリミジンの治療適用
JP2004523540A (ja) 形質転換成長因子β（ＴＧＦ−β）阻害剤としての２−アミノ−４−（ピリジン−２−イル）−チアゾール誘導体
JPH04230681A (ja) １，４‐ベンゾチアゼピン誘導体
CA3226869A1 (fr) Derives de pyridine substitues en tant qu'inhibiteurs de sarm1
US6262103B1 (en) Thienycyclohexanone derivatives as ligands of the GABAA α5 receptor subtype
US5063237A (en) 1,4-dihydro-2-(4-[benzimidazol-l-yl]phenyl)-pyridines as platelet activating factor antagonists
EP3383388B1 (fr) Utilisation d'arylacylsulfonamides en tant qu'antagonistes de blt1
EP3383869B1 (fr) Sulfonamides d'aryle utilisés en tant qu'antagonistes de blt1
EP3250561A1 (fr) Modulateurs indole de rorc2 substitués par sulfonamide et leurs procédés d'utilisation
US5877175A (en) Pharmaceutical compositions
KR101676889B1 (ko) 페닐이미다졸 화합물
EP3383868B1 (fr) Sulfonamides d'aryle utilisés en tant qu'antagonistes de blt1
EP3397627B1 (fr) Dérivés d'indolizine, composition et méthodes d'utilisation
WO2003080617A1 (fr) Derives pyrazolopyrimidines
JPH11302280A (ja) チアゾリジン誘導体、およびその誘導体を有効成分とする医薬
BG100209A (bg) Пиролохинолинонови производни с позитивна инотропна и лузитропна активност
JPH06199855A (ja) ピラゾロピリジン誘導体及びこれを含有する血小板凝集抑制剤